Cutaneous ␤-human papillomavirus (␤-HPV) E6 proteins inhibit NOTCH signaling by associating with the transcriptional coactivator MAML1. NOTCH has tumor suppressor activities in epithelial cells and is activated during keratinocyte differentiation. Here we report that HPV type 8 (HPV8) E6 subverts NOTCH activation during keratinocyte differentiation by inhibiting RBPJ/MAML1 transcriptional activator complexes at NOTCH target DNA. NOTCH inhibition impairs epithelial differentiation and may thus contribute to ␤-HPV replication and viral oncogenesis.
P
apillomaviridae are a large family of epitheliotropic viruses with double-stranded circular ϳ8-kb DNA genomes. More than 150 human papillomaviruses (HPVs) have been isolated (1) . Some HPVs infect mucosal epithelia, whereas other HPVs infect cutaneous epithelial cells. HPV infections can be nonsymptomatic or cause hyperplastic skin lesions, commonly referred to as warts. Mucosal ␣-HPVs have been studied in great detail since some of these viruses, the "high-risk" HPVs, are the causative agents of cervical carcinoma as well as other anogenital cancers and oropharyngeal carcinomas. Cutaneous ␤-HPVs are less studied. While ␤-HPVs appear to be part of the normal "skin flora" and infections are often asymptomatic, they can cause cutaneous warts, which undergo malignant progression in patients suffering from the rare genetic disease epidermodysplasia verruciformis (EV) or in systemically immune-suppressed organ transplant patients, particularly in sun-exposed areas of the body (2) (3) (4) (5) . ␤-HPVs may also contribute to nonmelanoma skin cancers (NMSCs) in patients with a normal immune system, but this has not been formally proven.
Cutaneous ␤-HPV E6 proteins have intrinsic transforming activities (6, 7) but do not associate with known cellular target proteins of high-risk mucosal ␣-HPV E6 proteins, including p53, UBE3A, and cellular PDZ proteins (8) . Several groups have recently reported that the E6 proteins from HPV5, HPV8, and other ␤-HPVs can bind the NOTCH coactivator mastermind-like 1 (MAML1), thereby inhibiting NOTCH transcriptional programs (9) (10) (11) . This is particularly interesting since NOTCH functions as a tumor suppressor in epithelial cells and mice with expression of a dominant negative MAML in basal epithelial cells develop squamous cell carcinoma (12) . Since NOTCH signaling is important for cellular differentiation, we wanted to determine whether HPV8 E6 inhibits NOTCH signaling during keratinocyte differentiation. To experimentally address this issue, we generated populations of human keratinocytes immortalized with human telomerase reverse transcriptase (hTERT) (cl398) (13) and stably expressing amino-terminally hemagglutinin (HA)/FLAG epitopetagged HPV8 E6 (8E6-iHFKs) by lentiviral transduction. Vector-infected cells were generated as controls (C-iHFKs). To confirm the interaction of HPV8 E6 with components of the NOTCH transcriptional complex in these cells, we prepared lysates of 8E6-iHFKs and C-iHFKs in mammalian cell lysis buffer (MCLB; 50 mM Tris [pH 7.5], 150 mM NaCl, 0.5% NP-40) supplemented with one complete EDTA protease inhibitor cocktail tablet (Roche) per 50 ml and performed HA immunoprecipitations. As expected, MAML1 (no. 4608; Cell Signaling; 1:1,000 dilution) and intracellular NOTCH (ICN; D3B8; Cell Signaling; 1:1,000) were found in complex with HA/FLAG-tagged HPV8 E6 (Fig. 1A) . To confirm the significance of this interaction in iHFKs, we harvested total RNA and determined relative mRNA levels of the prototypical NOTCH target gene HES1 as well as MAML1 in comparison to GAPDH, first by synthesizing cDNAs using the Quantitect reverse transcription kit (Qiagen) and then by quantitative PCR using the Quantitect SYBR green PCR kit (Qiagen) with HES1, MAML1, and GAPDH qSTAR quantitative PCR (qPCR) primer pairs (Origene). In agreement with published studies in other cell types, we observed a reduction in HES1 mRNA levels in 8E6-iHFKs compared to C-iHFKs (0.59 Ϯ 0.11; P ϭ 0.0001; Student's t test) (Fig. 1B) (9-11 ).
Next, we tested whether HPV8 E6 can interfere with NOTCH activation during epithelial differentiation. Calcium treatment of keratinocytes has been widely used to study keratinocyte differentiation (14, 15) . Therefore, we tested if calcium treatment of iHFKs resulted in a NOTCH activity profile similar to that of differentiating skin, namely, a gradual but robust increase of signaling during differentiation (15) . 8E6-iHFKs and C-iHFKs were grown to confluence in standard keratinocyte serum-free media (KFSM) supplemented with bovine pituitary gland extract and epidermal growth factor (Gibco) and then switched to calcium-containing Dulbecco's modified Eagle medium (DMEM; Gibco) supplemented with 10% fetal bovine serum. Total RNA was harvested with an RNAeasy Plus minikit (Qiagen) at days 0, 3, 4, 5, and 6 after calcium treatment, and relative mRNA levels of HES1 and MAML1 were determined as described for Fig. 1B . In C-iHFKs, we observed a steady increase in HES1 and MAML1 transcripts over the course of the experiment ( Fig. 2A) . In contrast, however, HES1 mRNA levels were lower in 8E6-iHFKs than in C-iHFKs even at late time points, while MAML1 transcript levels over the same period of time were only modestly lower than those in C-iHFKs (Fig. 2B) . If the differences in HES1 mRNA expression in C-iHFKs and 8E6-iHFKs were caused by HPV8 E6-mediated inhibition of NOTCH signaling, then chemical inhibition of NOTCH activation in C-iHFKs would similarly interfere with stimulation of HES1 mRNA expression during keratinocyte differentiation. To explore this possibility, we treated C-iHFKs with 2 M compound E (CpdE) (Millipore), a gamma secretase inhibitor (GSI). Gamma secretase cleaves membrane-bound NOTCH and causes release of the intracellular NOTCH (ICN) fragment. ICN then relocalizes to the nucleus, where it assembles with the DNA binding protein recombination signal binding protein for immunoglobulin kappa J (RBPJ), MAML family member coactivators, and other coactivators such as p300/CBP into a transcriptional activator complex.
Vehicle (dimethyl sulfoxide [DMSO])-treated C-iHFKs and 8E6-iHFKs were used as controls. Cells were calcium differentiated as described above, and total RNA was collected at days 0, 3, and 6 and analyzed by quantitative reverse transcription-PCR (qRT-PCR) (Fig. 2C ). Both 8E6-iHFKs and C-iHFKs treated with GSI showed similar reductions in HES1 mRNA levels at days 0 and 6 (P ϭ 0.0003 and 0.0001 at day 0 and 0.031 and 0.049 at day 6 for GSI-treated C-iHFKs and 8E6-iHFKs, respectively). At day 3 only
FIG 3
Immunoblot analysis of NOTCH signaling components and bona fide NOTCH-regulated genes. Protein extracts from C-iHFKs and 8E6-iHFKs treated with either DMSO or 2 M CpdE (GSI) were prepared at the indicated times from calcium-differentiated C-HFKs and 8E6-iHFKs. Steady-state levels of various NOTCH signaling-associated proteins were quantified using ImageJ software. Data shown are representative of two independent experiments.
FIG 2
Calcium-induced differentiation of iHFKs activates NOTCH signaling, which is inhibited in HPV8 E6-expressing iHFKs. C-iHFKs (A) and 8E6-iHFKs (B) were grown to 80% confluence in KSFM and then switched to Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum. RNA was isolated at various times, and HES1 and MAML1 mRNA levels were measured by qRT-PCR. HES1 and MAML1 mRNA levels dramatically increase upon calcium treatment of C-iHFKs, whereas there is only a slight increase in HES1 and MAML1 mRNA expression in 8E6-iHFKs. A representative experiment is shown; similar results were obtained in 2 additional experiments. Error bars show standard deviations from technical replicates of the qRT-PCR experiment shown. (C) NOTCH inhibition by a gamma secretase inhibitor (2 M CpdE-GSI) abrogates induction of HES1 mRNA expression and HPV8 E6 expression similarly at both day 0 and day 6 after calcium addition. Preparation of cells was similar to that for panels A and B except for CpdE and DMSO (vehicle) addition as shown. ‫,ء‬ P Ͻ 0.05 compared to results for C-iHFK (DMSO). Data represent averages and standard deviations from two independent experiments. 8E6-iHFKs were significantly different from vehicle-treated CiHFKs (P ϭ 0.0026).
We next analyzed levels of proteins participating in NOTCH signaling during keratinocyte differentiation and determined whether NOTCH inhibition by GSI in C-iHFKs had effects similar to those of HPV8 E6 expression. Lysates were prepared in MCLB from 8E6-iHFKs and C-iHFKs treated with either DMSO or GSI at days 0, 3, and 6 after calcium differentiation. In addition to levels of MAML1 (4608; Cell Signaling; 1:1,000), we examined levels of ICN1 (D3B8; Cell Signaling; 1:1,000), the stem cell marker p63 (H-137; Santa Cruz; 1:1,000), the NOTCH transcriptional target p21 CIP1 (15) (DCS60; Cell Signaling; 1:2,000), histone deacetylase 1 (HDAC1) (10E2; Cell Signaling; 1:1,000), and the epithelial differentiation marker involucrin (SY5; Thermo Scientific; 1:100) by immunoblotting. Signals were quantified by densitometric analysis of X-ray film using ImageJ software. ICN1 levels were initially high in both DMSO-treated C-iHFKs and 8E6-iHFKs and progressively decreased over time. GSI-treated CiHFKs and 8E6-iHFKs showed no detectable ICN1, confirming that CpdE potently inhibited gamma secretase activity (Fig. 3) . MAML1 levels increased in C-iHFKs during calcium treatment, but lower MAML1 levels were detected in 8E6-iHFKs and GSItreated cells. In DMSO-treated C-iHFKs, involucrin levels steadily increased during the time course of calcium differentiation. At each time point involucrin levels were similarly lower in DMSOtreated 8E6-iHFKs and GSI-treated C-iHFKs. GSI treatment of 8E6-iHFKs caused a further decrease of involucrin. These results suggest that HPV8 E6 impairs epithelial differentiation and inhibits NOTCH activity similar to GSI treatment, but not necessarily by completely overlapping mechanisms. Levels of the p53 family member and epithelial stem cell marker p63 remained higher only in differentiating 8E6-iHFKs and were only modestly affected by GSI, suggesting that p63 expression in differentiating 8E6-iHFKs may not be strictly NOTCH dependent. The two forms of p63 at day 0 may represent isoforms either lacking (⌬Np63) or containing (TAp63) the transactivation domain (16) . The levels of
FIG 4
Comparative analysis of NOTCH signaling pathway components in calcium-differentiated 8E6-iHFKs and GSI-treated C-HFKs by qRT-PCR. 8E6-iHFKs treated with DMSO and C-iHFKs treated with either DMSO or CpdE (2 M) were grown for 6 days in calcium differentiation medium, and total RNA was collected and analyzed using the human NOTCH signaling pathway PCR array (SABiosciences). Genes corresponding to those identified in the KEGG NOTCH pathway are displayed, with relative mRNA levels compared to those for differentiated C-iHFKs treated with DMSO indicated using the color scheme shown at the bottom. Results represent averages from duplicate PCR arrays.
HDAC1, a corepressor found in repressive RBPJ complexes, were reduced in 8E6-iHFKs as well as in cells treated with GSI. Lastly, the levels of p21 CIP1 , which in previous studies was identified as a NOTCH-induced mediator of G 1 /S cell cycle arrest during keratinocyte differentiation (15) , increased during early stages of CiHFK differentiation. Overall levels of p21 CIP1 were decreased in 8E6-iHFKs but not in cells treated with GSI. This indicates that HPV8 E6 may be able to retard cell cycle exit of differentiating epithelial cells but that the increase in p21 CIP1 during keratinocyte differentiation is largely independent of NOTCH signaling. These results suggest that inhibition of NOTCH signaling by HPV8 E6 expression or GSI treatment has overlapping yet distinct effects on NOTCH pathway protein expression.
To more globally explore HPV8 E6-mediated inhibition of NOTCH signaling during keratinocyte differentiation and differences between HPV8 E6-and GSI-mediated NOTCH inhibition, we utilized a qRT-PCR-based NOTCH pathway array (SABiosciences). The array analyzes the transcript levels of 84 genes associated with NOTCH signaling. Total RNA was prepared from untreated C-iHFKs, C-iHFKs and 8E6-iHFKs differentiated with calcium for 6 days, and C-iHFKs differentiated with calcium and treated with GSI for 6 days. Relative mRNA levels were determined by comparing levels detected in calcium-differentiated 8E6-iHFKs (Fig. 4A ) and in calcium-differentiated GSI-treated C-iHFKs (Fig. 4B) to those in calcium-differentiated C-iHFKs. We focused this analysis on genes represented in the Kyoto Encyclopedia of Genes and Genomes (KEGG) NOTCH signaling pathway and a few additional NOTCH pathway genes (Fig. 4) . Comparing HPV8 E6 NOTCH inhibition in C-iHFKs with GSImediated NOTCH inhibition, we detected decreases in expression of direct NOTCH target genes, consistent with inhibition of NOTCH signaling by both HPV8 E6 and GSI treatment. As we had observed in our analysis of NOTCH pathway protein expression (Fig. 3) , HPV8 E6 expression and GSI treatment have overlapping but not identical effects on NOTCH pathway gene expression ( Fig. 4; Table 1 ). This suggests that inhibition of NOTCH signaling by HPV8 E6 through MAML coactivator binding is different from global inhibition of NOTCH activation at the level of NOTCH receptor processing.
Hence, we sought to elucidate the mechanism by which HPV8 E6 may be functioning to impair NOTCH signaling. Previous work has shown that HPV8 E6 binds to an LXXLL motif within the carboxyl-terminal region of the poorly characterized MAML1 transactivation domain 2 (TAD2) (9, 10) . However, the mechanism by which HPV8 E6 inhibits NOTCH signaling through this interaction is unknown. One possibility is that E6 binding displaces MAML1 from DNA-bound RBPJ. In this case, HPV8 E6 expression, similar to GSI treatment, would prevent formation of the MAML1/p300-containing transcriptional activator complex on target-DNA-bound RBPJ and NOTCH target genes would remain in a repressed state. Alternatively, E6 may inhibit binding of one or more proteins necessary for MAML1 coactivator activity and would inhibit or inactivate the DNA-bound RBPJ/MAML1/ p300 transcriptional activator complex (Fig. 5A) . To distinguish between these two possibilities, we performed chromatin immunoprecipitation (ChIP). Briefly, we grew cells as described below and investigated the binding of HA/FLAG-tagged HPV8 E6 to functional RBPJ binding sites of the HES1 gene using EZChIP (Millipore). The HES1 promoter has two well-characterized RBPJ binding sites adjacent to the promoter that are required for NOTCH-mediated transcription (17) . An additional RBPJ binding site important for HES1 expression in response to NOTCH activation approximately 5,000 bp upstream of the promoter has also been described (18) . These sites in the HES1 enhancer (forward, 5= CCTCCCAGGATAGCTCTTG 3=; reverse, 5= TTTGCCT GAGGACTTGAAGC 3=) and promoter (forward, 5= CAAGACC AAAGCGGAAAGAA 3=; reverse, 5= GGTACCTGTGTGATCCCT AGGC 3=) were assessed using specific primer pairs (Fig. 5B) . The a To determine changes induced by differentiation, NOTCH pathway transcript levels obtained from PCR arrays in Fig. 4 were compared to transcript levels from C-iHFKs treated with DMSO but no calcium (day 0). Genes involved in NOTCH signaling occurring at the cell surface such as genes encoding ligands, receptors, and gamma secretase complex components, are distinguished from genes involved "nuclear" signaling such as those encoding coactivators and direct NOTCH transcriptional targets.
HA signal was higher at both the HES1 enhancer and promoter sites in 8E6-iHFKs than in C-iHFKs (Fig. 5C ). This suggested that HPV8 E6 can bind to NOTCH-responsive RBPJ target sites. MAML binding to RBPJ requires a composite ICN/RBPJ binding groove, and thus MAML cannot bind either of the factors independent of the other (18) . It has been reported that HPV8 E6 binds to MAML directly and subsequently indirectly to RBPJ and ICN (9) . To address whether HPV8 E6 requires ICN to access DNA, we performed ChIP on 8E6-iHFKs with or without GSI (2 M CpdE) treatment for occupancy of HA/FLAG-tagged HPV8 E6, RBPJ, and RNA polymerase II (Pol II). As expected, GSI treatment reduced occupancy of HPV8 E6 at both regulatory sites (Fig. 5D) . The apparent residual binding of HPV8 E6 to RBPJ in GSI-treated cells may reflect unspecific DNA binding by the HA antibody, the presence of ICN below the level of detection by Western blotting, or an interaction of HPV8 E6 with RBPJ through MAML-independent mechanisms, such as association with p300/CBP (19) . GSI treatment of 8E6-iHFKs also reduced the signal of RBPJ and Pol II at both HES1 sites (Fig. 5D ). In summary, we report that HPV8 E6 inhibits NOTCH activation during keratinocyte differentiation. This may provide a mechanistic explanation of earlier studies in organotypic raft cultures that showed that HPV8 E6 expression causes hyperproliferation and delayed differentiation (20) . Moreover, HPV8 E6 perturbs NOTCH target gene expression through a mechanism causing inhibition of RBPJ/MAML1 transcriptional activator complexes at NOTCH target DNA. This is distinct from the effects of GSIs, which inhibit ICN production and hence cause persistent formation of DNA-bound RBPJ transcriptional repressor complexes (Fig. 5A ). These mechanistic differences may account for the differences that we have observed in expression of NOTCH target genes in calcium-differentiated HPV8 E6-expressing and GSI-treated HFKs. Further studies will be focused on a detailed analysis of the mechanism of NOTCH inhibition by ␤-HPV-encoded E6 proteins and the biological implications of inhibition.
